Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

NCT02953704 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02953704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02953704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy
Lead sponsor
Incyte Corporation
Phase
Observational
Overall status
Completed
Start date
December 31, 2016
Completion date
March 29, 2022
Enrollment
1,469 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

mpn (myeloproliferative neoplasms)